| Mark P Kallaway, MD | |
|
1501 W Chisholm St, Alpena, MI 49707-1401 | |
| (989) 356-7390 | |
| (989) 356-7794 |
| Full Name | Mark P Kallaway |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Location | 1501 W Chisholm St, Alpena, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396835146 | NPI | - | NPPES |
| P00108478 | Other | MI | MICHIGAN |
| 0500401082 | Other | MI | BCBS MICHIGAN |
| 4452025 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 4301070855 (Michigan) | Primary |
| Entity Name | Insight Anesthesia Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952775975 PECOS PAC ID: 4486066297 Enrollment ID: O20201221001732 |
News Archive
Optimists live longer than pessimists and have a lower risk of chronic disease - this has been scientifically validated on multiple occasions.
Many people turn to artificial or so-called natural sweeteners to cut calories and lose weight. A new study led by Dr. Raylene Reimer, PhD, published in the high-impact journal Gut discovered that the consumption of low-calorie sweeteners while pregnant increased body fat in their offspring and disrupted their gut microbiota - the trillions of bacteria and other microorganisms that inhabit the intestinal tract and affect our health and risk of numerous diseases.
Mersana Therapeutics today announced the initiation of a Phase 1b extension study with its lead cancer product, XMT-1001, a novel DNA topoisomerase I inhibitor based on the company's Fleximer® polymer conjugate platform, in second-line gastric cancer and second-/third-line non-small cell lung cancer. The study will be carried out in 10 clinical centers in the US.
UC San Diego Health, with the University of California, San Diego School of Medicine, has entered into a multi-year affiliation agreement with La Jolla Institute for Allergy and Immunology designed to deepen existing collaborative relationships, boost basic research of diseases of the immune system and more quickly introduce new clinical treatments and therapies.
In a study published in the current online issue of JAMA Psychiatry, an international team of scientists, led by researchers at the University of California, San Diego School of Medicine, report finding a highly accurate blood-based measure that could lead to development of a clinical test for autism spectrum disorder (ASD) risk in males as young as one to two years old.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark P Kallaway, MD 9750 Us Highway 23 N, Alpena, MI 49707-8948 Ph: () - | Mark P Kallaway, MD 1501 W Chisholm St, Alpena, MI 49707-1401 Ph: (989) 356-7390 |
News Archive
Optimists live longer than pessimists and have a lower risk of chronic disease - this has been scientifically validated on multiple occasions.
Many people turn to artificial or so-called natural sweeteners to cut calories and lose weight. A new study led by Dr. Raylene Reimer, PhD, published in the high-impact journal Gut discovered that the consumption of low-calorie sweeteners while pregnant increased body fat in their offspring and disrupted their gut microbiota - the trillions of bacteria and other microorganisms that inhabit the intestinal tract and affect our health and risk of numerous diseases.
Mersana Therapeutics today announced the initiation of a Phase 1b extension study with its lead cancer product, XMT-1001, a novel DNA topoisomerase I inhibitor based on the company's Fleximer® polymer conjugate platform, in second-line gastric cancer and second-/third-line non-small cell lung cancer. The study will be carried out in 10 clinical centers in the US.
UC San Diego Health, with the University of California, San Diego School of Medicine, has entered into a multi-year affiliation agreement with La Jolla Institute for Allergy and Immunology designed to deepen existing collaborative relationships, boost basic research of diseases of the immune system and more quickly introduce new clinical treatments and therapies.
In a study published in the current online issue of JAMA Psychiatry, an international team of scientists, led by researchers at the University of California, San Diego School of Medicine, report finding a highly accurate blood-based measure that could lead to development of a clinical test for autism spectrum disorder (ASD) risk in males as young as one to two years old.
› Verified 6 days ago
Vicki Kottong, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1501 W Chisholm St, Alpena, MI 49707 Phone: 989-356-7390 Fax: 989-356-8013 | |
Sean M Rivard, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1501 W Chisholm St, Alpena, MI 49707 Phone: 989-356-7284 Fax: 989-356-8013 | |
Dr. David Randall Meinhardt, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1501 W Chisholm St, Alpena, MI 49707 Phone: 989-356-7390 | |
Robert J Coombs, D.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1063 Us 23 N, Alpena, MI 49707 Phone: 989-358-6824 | |
Kevin A Kozicz, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1501 W Chisholm St, Alpena, MI 49707 Phone: 989-356-7390 Fax: 989-356-8013 | |
Teresa E Griffith, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1501 W Chisholm St, Alpena, MI 49707 Phone: 989-356-7390 Fax: 989-356-8013 |